Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 145 added to statin therapy in primary hypercholesterolemia or mixed dyslipidemia
2012-001363-70Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in hypercholesterolemia and combined dyslipidaemia (4 arms), sponsored by Amgen. Started Aug 2012; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2012-001363-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001363-70.